The urotension II antagonist SB-710411 arrests fibrosis in CCL4 cirrhotic rats.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Molecular Medicine Reports

• Publication date

  2009-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/mmr_00000198PMID 21475927
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatic stellate cells and liver fibrosis.

  2009cited by this paper
• Urotensin-II and cardiovascular remodeling.

  2008cited by this paper
• Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function.

  2008cited by this paper
• Newly proposed fibrosis staging criterion for assessing carbon tetrachloride‐ and albumin complex‐induced liver fibrosis in rodents

  2008cited by this paper
• Regulation of Sinusoidal Perfusion in Portal Hypertension

  2008cited by this paper
• Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues

  2008cited by this paper
• Mechanisms of hepatic fibrogenesis.

  2008cited by this paper
• Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension

  2007cited by this paper
• The Angiotensin II Receptor Antagonist Candesartan Is Not Effective in Reducing Portal Hypertension in Patients with Cirrhosis

  2007cited by this paper
• Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats

  2007cited by this paper
• The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts.

  2007cited by this paper
• The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats

  2006cited by this paper
• Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis.

  2006cited by this paper
• Urotensin II Modulates Rapid Eye Movement Sleep through Activation of Brainstem Cholinergic Neurons

  2005cited by this paper
• Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking.

  2004cited by this paper
• Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.

  2004cited by this paper
• Human Urotensin II Modulates Collagen Synthesis and the Expression of MMP-1 in Human Endothelial Cells

  2004cited by this paper
• [Mechanisms of hepatic fibrogenesis].

  2002cited by this paper
• Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist

  2002cited by this paper
• Extracellular Matrix Degradation and the Role of Hepatic Stellate Cells

  2001cited by this paper
• Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.

  2001cited by this paper
• Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats.

  2001cited by this paper
• Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C

  2001cited by this paper
• Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

  2001cited by this paper
• Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology

  2000cited by this paper
• Angiotensin II induces contraction and proliferation of human hepatic stellate cells.

  2000cited by this paper
• Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects.

  1999cited by this paper
• Class VI intermediate filament protein nestin is induced during activation of rat hepatic stellate cells

  1999cited by this paper
• Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis

  1999cited by this paper
• Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Immunohistochemical study on phenotypical changes of hepatocytes in liver disease with reference to extracellular matrix composition.

  1999cited by this paper
• Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential.

  1999cited by this paper
• Beneficial hemodynamic effects of bosentan, a mixed ETA and ETB receptor antagonist, in portal hypertensive rats

  1998cited by this paper
• Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis.

  1996cited by this paper
• Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis

  1996cited by this paper
• Novel insights into the biology and physiology of the Ito cell.

  1995cited by this paper
• Hepatocyte-matrix interactions.

  1994cited by this paper
• Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies.

  1993cited by this paper
• Enzyme immunoassay techniques. An overview.

  1992cited by this paper

• Urotensin-II receptor contributes to the pro-inflammatory TLR4/MyD88/NF-κB/iNOS/NO pathway-mediated cardiovascular response to systemic lipopolysaccharide challenge in a septic shock model in rats.

  2025cites this paper
• Urotensin II system in chronic kidney disease

  2024cites this paper
• EXPLORATION OF THE UROCONTRIN A SCAFFOLD YIELDS NEW UROTENSINERGIC SYSTEM ALLOSTERIC MODULATOR AND COMPETITIVE ANTAGONISTS.

  2023cites this paper
• Effects of Alpha-Lipoic Acid on TGF-β1 and Urotensin-II Levels in Glucocorticoid-Induced Osteonecrosis in Rats

  2020cites this paper
• Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats

  2019cites this paper
• Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.

  2019cites this paper
• Urotensin II: an inflammatory cytokine.

  2019cites this paper
• Towards Targeting the Urotensinergic System: Overview and Challenges.

  2019cites this paper
• Endothelin-1 and angiotensin-II modulate urotensin-II vasoconstriction in rat aorta exposed to mercury.

  2018cites this paper
• Lysyl hydroxylase 2b the X factor in OA-related synovial fibrosis. The cause of joint stiffness in OA?

  2015cites this paper
• Unravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness.

  2015cites this paper
• Utility of Translocator Protein (18 kDa) as a Molecular Imaging Biomarker to Monitor the Progression of Liver Fibrosis

  2015cites this paper
• Urotensin II (U-II), a novel cyclic peptide, possibly associated with the pathophysiology of osteoarthritis.

  2014cites this paper
• H2S inhibits the activation of hepatic stellate cells and downregulates the expression of urotensin II

  2013cites this paper
• Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension.

  2010cites this paper